{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:07:58Z","timestamp":1792181278727,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Protein biomarkers and microheterogeneity have attracted increasing attention in epidemiological and clinical research. Knowledge of within-person reproducibility over time is paramount to determine whether a single measurement accurately reflects an individual\u2019s long-term exposure. Yet, research investigating within-person reproducibility for proteoforms is limited. We investigated the reproducibility of the inflammatory markers C-reactive protein (CRP), serum amyloid A (SAA), and calprotectin (S100A8\/9), and the renal function marker cystatin C (CnC) using a novel immuno-MALDI-TOF MS assay. Reproducibility, expressed as intraclass correlation coefficient (ICC), was calculated for 16 proteoforms using plasma samples of the Western Norway B Vitamin Intervention Trial (WENBIT) cohort collected 1\u20133\u00a0y apart from 295 stable angina pectoris (SAP) patients and 16\u00a0weeks apart from 38 subjects of the Intervention with Omega Fatty Acids in High-risk Patients with Hypertriglyceridemic Waist (OMEGA) trial with abdominal obesity but no other documented co-morbidities. ICCs for inflammatory markers were lower in WENBIT (CRP: 0.51, SAAt: 0.38, S100At: 0.31) compared to OMEGA subjects (CRP: 0.71, SAAt: 0.73, S100At: 0.48), while comparable for CnCt (WENBIT: 0.69, OMEGA: 0.67). Excluding SAP patients with elevated inflammation (CRP\u2009&gt;\u200910\u00a0\u00b5g\/ml) increased the ICC of SAAt to 0.55. Reduction of the time interval from 3 to 1\u00a0y in WENBIT group increased ICCs for all proteoforms. With a few exceptions ICCs did not differ between proteoforms of the same biomarker. ICCs were highest in OMEGA subjects with fair-to-good reproducibility for all markers. Reproducibility of SAA and S100A8\/9 proteoforms in the WENBIT cohort was related to inflammation. This work will inform future clinical and epidemiological research which relies on single time point biomarker assessment to investigate inflammation and renal function.<\/jats:p>","DOI":"10.1038\/s41598-022-11520-1","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T09:06:04Z","timestamp":1651827964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Within-person reproducibility of proteoforms related to inflammation and renal dysfunction"],"prefix":"10.1038","volume":"12","author":[{"given":"Jie","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Laupsa-Borge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottar","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Magne","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"11520_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/03009734.2012.668143","volume":"117","author":"L Berglund","year":"2012","unstructured":"Berglund, L. Regression dilution bias: tools for correction methods and sample size calculation. Ups. J. Med. Sci. 117, 279\u2013283 (2012).","journal-title":"Ups. J. Med. Sci."},{"key":"11520_CR2","unstructured":"Rosner, B. One-way ANOVA-the random-effects model. In Fundamentals of Biostatistics 613\u2013618 (Duxbury) (2006)."},{"key":"11520_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s10552-006-0035-5","volume":"17","author":"SS Tworoger","year":"2006","unstructured":"Tworoger, S. S. & Hankinson, S. E. Use of biomarkers in epidemiologic studies: Minimizing the influence of measurement error in the study design and analysis. Cancer Causes Control 17, 889\u2013899 (2006).","journal-title":"Cancer Causes Control"},{"key":"11520_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nbt1235","volume":"24","author":"N Rifai","year":"2006","unstructured":"Rifai, N., Gillette, M. A. & Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971\u2013983 (2006).","journal-title":"Nat. Biotechnol."},{"key":"11520_CR5","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1039\/c0an00204f","volume":"135","author":"JF Rusling","year":"2010","unstructured":"Rusling, J. F., Kumar, C. V., Gutkind, J. S. & Patel, V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst 135, 2496\u20132511 (2010).","journal-title":"Analyst"},{"key":"11520_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nchembio.2576","volume":"14","author":"R Aebersold","year":"2018","unstructured":"Aebersold, R. et al. How many human proteoforms are there?. Nat. Chem. Biol. 14, 206\u2013214 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"11520_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.tibs.2019.12.009","volume":"45","author":"A Bogaert","year":"2020","unstructured":"Bogaert, A., Fernandez, E. & Gevaert, K. N-terminal proteoforms in human disease. Trends Biochem. Sci. 45, 308\u2013320 (2020).","journal-title":"Trends Biochem. Sci."},{"key":"11520_CR8","doi-asserted-by":"publisher","first-page":"10852","DOI":"10.1073\/pnas.0500426102","volume":"102","author":"D Nedelkov","year":"2005","unstructured":"Nedelkov, D. et al. Investigating diversity in human plasma proteins. Proc. Natl. Acad. Sci. U. S. A. 102, 10852\u201310857 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"11520_CR9","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/nbt1252","volume":"24","author":"G Walsh","year":"2006","unstructured":"Walsh, G. & Jefferis, R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24, 1241\u20131252 (2006).","journal-title":"Nat. Biotechnol."},{"key":"11520_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12014-020-09283-w","volume":"17","author":"A Macklin","year":"2020","unstructured":"Macklin, A., Khan, S. & Kislinger, T. Recent advances in mass spectrometry based clinical proteomics: Applications to cancer research. Clin. Proteom. 17, 17 (2020).","journal-title":"Clin. Proteom."},{"key":"11520_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/proteomes4010013","volume":"4","author":"O Trenchevska","year":"2016","unstructured":"Trenchevska, O., Nelson, R. W. & Nedelkov, D. Mass spectrometric immunoassays in characterization of clinically significant proteoforms. Proteomes 4, 13 (2016).","journal-title":"Proteomes"},{"key":"11520_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/clinchem\/hvz022","volume":"66","author":"H Neubert","year":"2020","unstructured":"Neubert, H. et al. Protein biomarker quantification by immunoaffinity liquid chromatography-tandem mass spectrometry: Current state and future vision. Clin. Chem. 66, 282\u2013301 (2020).","journal-title":"Clin. Chem."},{"key":"11520_CR13","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1021\/acs.analchem.7b04975","volume":"90","author":"J Gao","year":"2018","unstructured":"Gao, J., Meyer, K., Borucki, K. & Ueland, P. M. Multiplex immuno-MALDI-TOF MS for targeted quantification of protein biomarkers and their proteoforms related to inflammation and renal dysfunction. Anal. Chem. 90, 3366\u20133373 (2018).","journal-title":"Anal. Chem."},{"key":"11520_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jama.300.7.795","volume":"300","author":"M Ebbing","year":"2008","unstructured":"Ebbing, M. et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA 300, 795\u2013804 (2008).","journal-title":"JAMA"},{"key":"11520_CR15","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1016\/j.clnu.2021.03.040","volume":"40","author":"E Grytten","year":"2021","unstructured":"Grytten, E. et al. Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study. Clin. Nutr. 40, 2556\u20132575 (2021).","journal-title":"Clin. Nutr."},{"key":"11520_CR16","doi-asserted-by":"publisher","first-page":"121774","DOI":"10.1016\/j.talanta.2020.121774","volume":"223","author":"J Gao","year":"2021","unstructured":"Gao, J. et al. Microheterogeneity and preanalytical stability of protein biomarkers of inflammation and renal function. Talanta 223, 121774 (2021).","journal-title":"Talanta"},{"key":"11520_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout, P. E. & Fleiss, J. L. Intraclass correlations: Uses in assessing rater reliability. Psychol. Bull. 86, 420\u2013428 (1979).","journal-title":"Psychol. Bull."},{"key":"11520_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1161\/01.CIR.0000115516.54550.B1","volume":"109","author":"BD Johnson","year":"2004","unstructured":"Johnson, B. D. et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women\u2019s Ischemia Syndrome Evaluation (WISE). Circulation 109, 726\u2013732 (2004).","journal-title":"Circulation"},{"key":"11520_CR19","doi-asserted-by":"publisher","first-page":"e0125992","DOI":"10.1371\/journal.pone.0125992","volume":"10","author":"SB Larsen","year":"2015","unstructured":"Larsen, S. B. et al. Calprotectin and platelet aggregation in patients with stable coronary artery disease. PLoS ONE 10, e0125992 (2015).","journal-title":"PLoS ONE"},{"key":"11520_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1749-6632.1982.tb22153.x","volume":"389","author":"JJ Morley","year":"1982","unstructured":"Morley, J. J. & Kushner, I. Serum C-reactive protein levels in disease. Ann. N. Y. Acad. Sci. 389, 406\u2013418 (1982).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"11520_CR21","first-page":"141","volume-title":"Pathogenic Role of IL-6 Combined with TNF-\u03b1 or IL-1 in the Induction of Acute Phase Proteins SAA and CRP in Chronic Inflammatory Diseases","author":"K Yoshizaki","year":"2011","unstructured":"Yoshizaki, K. Pathogenic Role of IL-6 Combined with TNF-\u03b1 or IL-1 in the Induction of Acute Phase Proteins SAA and CRP in Chronic Inflammatory Diseases 141\u2013150 (Springer, 2011)."},{"key":"11520_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2362.1996.159291.x","volume":"26","author":"E Malle","year":"1996","unstructured":"Malle, E. & De Beer, F. C. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur. J. Clin. Investig. 26, 427\u2013435 (1996).","journal-title":"Eur. J. Clin. Investig."},{"key":"11520_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1161\/ATVBAHA.113.302432","volume":"34","author":"OS Cotoi","year":"2014","unstructured":"Cotoi, O. S. et al. Plasma S100A8\/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler. Thromb. Vasc. Biol. 34, 202\u2013210 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"11520_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.clinbiochem.2006.03.017","volume":"39","author":"A Ognibene","year":"2006","unstructured":"Ognibene, A. et al. Cystatin C reference values and aging. Clin. Biochem. 39, 658\u2013661 (2006).","journal-title":"Clin. Biochem."},{"key":"11520_CR25","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.atherosclerosis.2012.07.017","volume":"224","author":"EM DeGoma","year":"2012","unstructured":"DeGoma, E. M. et al. Intraindividual variability of C-reactive protein: The multi-ethnic study of atherosclerosis. Atherosclerosis 224, 274\u2013279 (2012).","journal-title":"Atherosclerosis"},{"key":"11520_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1253\/circj.70.559","volume":"70","author":"A Nasermoaddeli","year":"2006","unstructured":"Nasermoaddeli, A., Sekine, M. & Kagamimori, S. Intra-individual variability of high-sensitivity C-reactive protein: Age-related variations over time in Japanese subjects. Circ. J. 70, 559\u2013563 (2006).","journal-title":"Circ. J."},{"key":"11520_CR27","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/1055-9965.EPI-12-0110","volume":"21","author":"SL Navarro","year":"2012","unstructured":"Navarro, S. L. et al. Reliability of serum biomarkers of inflammation from repeated measures in healthy individuals. Cancer Epidemiol. Biomark. Prev. 21, 1167\u20131170 (2012).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"4","key":"11520_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/13547500600799748","volume":"11","author":"WK Al-Delaimy","year":"2006","unstructured":"Al-Delaimy, W. K. et al. Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts. Biomarkers 11(4), 370\u2013382 (2006).","journal-title":"Biomarkers"},{"key":"11520_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/archinternmed.2012.3712","volume":"172","author":"JK Bower","year":"2012","unstructured":"Bower, J. K., Lazo, M., Juraschek, S. P. & Selvin, E. Within-person variability in high-sensitivity C-reactive protein. Arch. Intern. Med. 172, 1519\u20131521 (2012).","journal-title":"Arch. Intern. Med."},{"key":"11520_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1684\/ecn.2009.0146","volume":"20","author":"F Linkov","year":"2009","unstructured":"Linkov, F. et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur. Cytokine Netw. 20, 21\u201326 (2009).","journal-title":"Eur. Cytokine Netw."},{"key":"11520_CR31","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/clinchem\/47.8.1498","volume":"47","author":"GM D\u2019Eril","year":"2001","unstructured":"D\u2019Eril, G. M., Anesi, A., Maggiore, M. & Leoni, V. Biological variation of serum amyloid A in healthy subjects [Letter]. Clin. Chem. 47, 1498\u20131499 (2001).","journal-title":"Clin. Chem."},{"key":"11520_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/jlpm.2019.12.01","volume":"5","author":"L Koelman","year":"2020","unstructured":"Koelman, L. et al. In pursuit of novel biomarkers reflecting intestinal inflammation: Temporal variability and phenotypic characterisation of serum calprotectin and lactoferrin. J. Lab. Precis. Med. 5, 11\u201321 (2020).","journal-title":"J. Lab. Precis. Med."},{"key":"11520_CR33","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1515\/CCLM.2007.256","volume":"45","author":"N Bandaranayake","year":"2007","unstructured":"Bandaranayake, N., Ankrah-Tetteh, T., Wijeratne, S. & Swaminathan, R. Intra-individual variation in creatinine and cystatin C. Clin. Chem. Lab. Med. 45, 1237\u20131239 (2007).","journal-title":"Clin. Chem. Lab. Med."},{"key":"11520_CR34","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/clinchem\/44.7.1535","volume":"44","author":"BG Keevil","year":"1998","unstructured":"Keevil, B. G., Kilpatrick, E. S., Nichols, S. P. & Maylor, P. W. Biological variation of cystatin C: Implications for the assessment of glomerular filtration rate. Clin. Chem. 44, 1535\u20131539 (1998).","journal-title":"Clin. Chem."},{"key":"11520_CR35","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/sim.1108","volume":"21","author":"DG Bonett","year":"2002","unstructured":"Bonett, D. G. Sample size requirements for estimating intraclass correlations with desired precision. Stat. Med. 21, 1331\u20131335 (2002).","journal-title":"Stat. Med."},{"key":"11520_CR36","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/ije\/dyz055","volume":"48","author":"KE Morgan","year":"2019","unstructured":"Morgan, K. E., Cook, S., Leon, D. A. & Frost, C. Reflection on modern methods: Calculating a sample size for a repeatability sub-study to correct for measurement error in a single continuous exposure. Int. J. Epidemiol. 48, 1721\u20131726 (2019).","journal-title":"Int. J. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11520-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11520-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11520-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:47:31Z","timestamp":1669344451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11520-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11520"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11520-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"27 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7426"}}